

**The Effects of the Neuropeptide Substance P on
Outcome Following Experimental Traumatic
Brain Injury in Rats**

JAMES J. DONKIN B.HSc. (Hons.)

Discipline of Pathology, School of Medical Sciences

University of Adelaide

August 2006

A thesis submitted in partial fulfilment of the requirements for the degree
of Doctor of Philosophy

*The brain is a wonderful organ. It starts
working the moment you get up in the
morning and does not stop until you get into
the office.*

Robert Frost (1874-1963)

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and that, to the best of my knowledge and belief, the thesis contains no material previously published or written by another person, except where due reference has been made in the text of the thesis.

I give consent to this copy of my thesis, when deposited in the University Library, being available for photocopying and loan.

Date

James Donkin

Dedication

This thesis is dedicated in memory of Ray Donkin and Ardiss Moran, who instilled in me the determination to succeed in everything I do.

Publications and Presentations

The following articles have been published or accepted for publication or presentation during the period of my PhD candidature, and sections of these articles have been included in the present thesis.

Journal Papers:

Van Den Heuvel C, **Donkin JJ**, Finnie JW, Blumbergs PC, Kuchel T, Koszyca B, Manavis J, Jones NR, Reilly PL and Vink R. (2004) Downregulation of amyloid precursor protein (APP) mRNA and antigen expression following post-traumatic cyclosporin-A administration. *J Neurotrauma* 21(11): 1562-72.

Vink R, **Donkin JJ**, Cruz MI, Nimmo A and Cernak I. (2004) A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. *J Am Coll Nutr* 23(5): 538S-540S.

Conference Papers:

Donkin JJ, Cernak I, Rodgers K and Vink R. (2004) Mild concussive head injury results in increased brain substance P immunoreactivity. In: *Proceedings of the 7th International Neurotrauma Symposium*, Adelaide, South Australia: 110

Abstracts and Posters:

Vink R, Cruz MI, **Donkin JJ**, Nimmo A and Cernak I. (2003) A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. *Magnesium Res* 16(4): 315.

Donkin JJ, Cernak I, Rodgers K and Vink R. (2004) Mild Concussive head injury results in increased brain substance P immunoreactivity. *Rest Neurol Neurosci* 23: 169

Howard C, **Donkin JJ**, Ghabriel M, Blumbergs PC and Vink R. (2004) A substance P antagonist increases aquaporin-4 expression and reduces oedema after traumatic brain injury. *Rest Neurol Neurosci* 23: 194

Donkin JJ, Nimmo AJ and Vink R. (2006) Delayed administration of a substance P antagonist at 12 h after diffuse traumatic brain injury improves outcome. *J Neurotrauma* 23: 778

Book Chapters

Donkin JJ, Turner R, Hassan I and Vink R (2006) A review of the role of neuropeptides in traumatic brain injury. In: *Progress in Brain Research. Neurotrauma: new insights into pathology and treatment* (Weber JT and Maas, AIR), Rotterdam: Elsevier, in press.

Acknowledgments

The decision to undertake this PhD has been very rewarding for me and has allowed me to explore many exciting areas and meet many interesting people. There is a touch of sadness to be finishing up my studying days at university where I have been for a third of my life. It has provided me with a sense of curiosity and an attitude of determination in all that I undertake. However to get to this point I have required the help and support of many people. I would like to acknowledge the Faculty of Health Sciences for awarding me the divisional scholarship to enable me to embark on the challenge.

First and foremost, to my mentor and friend, Prof Robert Vink. Your guidance as my supervisor throughout the entire candidature has been exceptional and one which I am forever thankful for. I thank you for sharing with me your immense research experiences and allowing me the opportunity to undertake the PhD in your lab. I find it amazing that with your busy schedule you were able to make time for me to bounce ideas off, seek advice or just have a friendly chat. Your door is always open and I am confident it always will be. I wish you all the luck for the future, especially in Eustralis.

Next, to my co-supervisor, Dr Corinna Van Den Heuvel. A friend and colleague who has taught me the whole way through, from the undergraduate level until now. You laid the foundation to my research life and always impart constant advice and expertise. I thank you, not just for your help but also your friendship, which we have developed over the years. You're a true legend and I wish you and the family all the best luck for the future.

To Renee, Emma, Tuyet, Islam, Felicity and more recently Naomi who have shared PhD life with me along the way. In particular, Renee and Emma, thank you for all your help with surgery, we were always there to support each other, especially when things didn't go well. I especially enjoyed the chats and laughs during our wine meetings. I wish you all well for the remainder of your studies and all the best for your future careers.

To all the people who have helped me throughout my studies, in particular Christine O'Connor, thank you for introducing me to brain injury and teaching me around the surgery. Your persona was fantastic around the lab, constantly having us in fits of laughter with your firm attitudes. You were the mother of the lab and were always there for a comforting talk when experiments weren't working. Other people who have helped along the way include Prof Peter Blumbergs, who offered informative advice and help with analysing slides. Jim Manavis and Kathryn Rodgers who taught and helped with immunohistochemistry. Ghafar Sarvestani for the confocal images and Dale Caville for making all my figures magnificent in this thesis.

To Mum and Dad, thank you for your tireless support and love throughout my life, especially during my studies. You had faith in me and believed that I would succeed. Also to the boys, thanks for the welcomed distractions along the way and the memes.

Last but not least, to Beck, who has put up with me throughout the entire PhD. Thank you for your love and patience, especially with my indecisiveness. I congratulate you too on finishing your PhD and look forward to our next adventure.

Abbreviations

A ₁	Adenosine
ACE	Angiotensin-Converting Enzyme
Ach	Acetylcholine
ADC	Apparent Diffusion Coefficient
ANOVA	Analysis of Variance
APP	Amyloid Precursor Protein
APT	3-Aminopropyl Triethoxysilane
ATP	Adenosine Triphosphate
BBB	Blood-Brain Barrier
B ₀	Maximum Binding
BP	Blood Pressure
Ca ²⁺	Calcium
cAMP	Cyclic Adenosine Monophosphate
CBF	Cerebral Blood Flow
CBV	Cerebral Blood Volume
CDC	Centre for Disease control and prevention
CCI	Controlled Cortical Impact
CGRP	Calcitonin-gene Related Peptide
Cl ⁻	Chloride
CNS	Central Nervous System
COOH-terminal	Carboxyl Terminal
CPP	Cerebral Perfusion Pressure

CREB	cAMP Response Element-Binding
CSF	Cerebrospinal Fluid
DA	Dopamine
DAB	Diaminobenzidine Tetrahydrochloride
DAI	Diffuse Axonal Injury
DNA	Deoxyribonucleic Acid
DPX	Depex Mountant
DRG	Dorsal Root Ganglion
DVI	Diffuse Vascular Injury
DWI	Diffusion Weighted Image
EAA	Excitatory Amino Acid
EB	Evans Blue
EC	Endothelial Cell
EDTA	Ethylenediaminetetra-acetic Acid
ELISA	Enzyme-Linked Immunosorbent Assay
eNOS	Endothelial Nitric Oxide Synthase
FP	Fluid Percussion
FPI	Fluid Percussion Injury
GABA	Gamma-aminobutyric acid
GCS	Glasgow Coma Scale
GI	Gastrointestinal
GOS	Glasgow Outcome Score
5-HT	5-hydroxytryptamine
H ₂ O ₂	Hydrogen Peroxide
H ₃	Histamine

H&E	Haematoxylin and Eosin
ICAM-1	Intercellular Adhesion Molecule 1
ICP	Intracranial Pressure
iNOS	Inducible Nitric Oxide Synthase
I.P.	Intra Peritoneal
I.V.	Intra Venous
IP ₃	Inositol 1,4,5-triphosphate
K ⁺	Potassium
LIS	Locked In Syndrome
LOC	Loss of Consciousness
MABP	Mean Arterial Blood Pressure
MCS	Minimally Conscious State
Mg ²⁺	Magnesium
MHC	Major Histocompatibility Complex
MRI	Magnetic Resonance Imaging
mRNA	Messenger Ribonucleic Acid
MTBI	Mild Traumatic Brain Injury
MWM	Morris Water Maze
Na ²⁺	Sodium
NAD	n-acetyl D-tryptophan
NAT	n-acetyl L-tryptophan
NBM	Nucleus Basalis Magnocellularis
NE	Norepinephrine
NEP	Neutral Endopeptidase
NHS	Normal Horse Serum

NK ₁	Neurokinin-1 Receptor
NK ₂	Neurokinin-2 Receptor
NK ₃	Neurokinin-3 Receptor
NKA	Neurokinin A
NKB	Neurokinin B
NMDA	N-methyl-D-aspartate
nNOS	Neuronal Nitric Oxide Synthase
NO	Nitric Oxide
NOS	Nitric Oxide Synthase
NPK	Neuropeptide K
NP γ	Neuropeptide γ
NSB	Non-specific Binding
PBS	Phosphate Buffered Solution
PCD	Programmed Cell Death
PCr	Phosphocreatine
PCS	Post-Concussion Syndrome
δ Pi	Inorganic Phosphate Peak
PM	Prospective Memory
PNS	Peripheral Nervous System
PPTA	Preprotachykinin A
PPTB	Preprotachykinin B
PTA	Post-traumatic Amnesia
PVS	Persistent Vegetative State
ROS	Reactive Oxygen Species
Rpm	Revolutions per Minute

SD	Standard Deviation
SEM	Standard Error of Measurement
SP	Substance P
SP-IR	Substance P-Immunoreactivity
SPC	Streptavidin Peroxidase Conjugate
TA	Total Activity
TAI	Traumatic Axonal Injury
TBI	Traumatic Brain Injury
TRH	Thyrotropin-Releasing Hormone
TRS	Target Retrieval Solution
TRIM	1-(2-trifluoromethylphenyl) imidazole
TRIMPOH	2-trifluoromethylphenol
UK	United Kingdom
VR-1	Vanilloid Receptor-1
WDR	Wide Dynamic Range
WHO	World Health Organisation

Table of Contents

PUBLICATIONS AND PRESENTATIONS	V
ACKNOWLEDGMENTS.....	VII
ABBREVIATIONS	IX
TABLE OF FIGURES.....	XIX
ABSTRACT	XXV
CHAPTER 1.....	1
INTRODUCTION.....	1
1.1 EPIDEMIOLOGY	4
1.1.1 Incidence and cause.....	4
1.2 NEUROPSYCHOLOGICAL CONSEQUENCES OF BRAIN INJURY.....	6
1.2.1 Mild Traumatic brain injury	7
1.2.2 Moderate Traumatic brain injury	8
1.2.3 Severe Traumatic brain injury	10
1.3 NEUROPATHOLOGY AND PATHOPHYSIOLOGY OF BRAIN INJURY	12
1.3.1 Primary traumatic brain injury mechanisms	13
1.3.2 Secondary traumatic brain injury mechanisms	19
1.3.3 Cell Death.....	22
1.4 TRAUMATIC BRAIN OEDEMA	24
1.4.1 Classification of oedema	25
1.4.2 temporal profile of oedema	27
1.4.3 Blood Brain Barrier Permeability	28
1.4.4 cerebral homeostasis and autoregulation	29
1.4.5 Treatment.....	31
1.5 SUBSTANCE P.....	33
1.5.1 Synthesis	33
1.5.2 Location	35
1.5.3 Localisation in the CNS.....	36
1.5.4 Localisation in the PNS.....	38
1.5.5 Enzymes	39
1.5.6 Receptors	40
1.5.7 NK ₁ receptors	40
1.5.8 Co-localisation of tachykinins.....	43
1.5.9 NK ₁ Receptor Internalisation	45
1.5.10 NK ₁ receptor agonists.....	46
1.5.11 NK ₁ receptor antagonists	47
1.5.12 Effects of SP	49
1.5.14 Neurogenic Inflammation.....	53
1.6 EXPERIMENTAL TBI MODELS.....	57
1.6.1 Fluid percussion injury.....	59
1.6.2 Controlled Cortical Impact Injury.....	59
1.6.3 Impact-acceleration injury model (closed skull-weight drop).....	60
1.6.4 Impact-acceleration injury model (closed skull-hydraulic piston).....	61
1.7 SYNOPSIS.....	62

CHAPTER 2 GENERAL METHODS	64
2.1 ANIMAL CARE.....	65
2.1.1 Ethics	65
2.1.2 General	65
2.2 EXPERIMENTAL PROCEDURES	65
2.2.1 Anaesthesia.....	65
2.2.2 Impact-Acceleration Injury (Weight-drop)	67
2.2.3 Impact-acceleration Injury (Hydraulic Piston)	69
2.2.4 Lateral Fluid percussion injury	72
2.2.5 Perfusion.....	73
2.3 DRUG TREATMENTS	73
2.3.1 N-acetyl L-Tryptophan	73
2.3.2 1-(2-Trifluoromethyl-Phenyl) Imidazole	74
2.4 FUNCTIONAL TESTS	74
2.4.1 Rotarod.....	74
2.4.2 Cognitive Outcome	77
2.5 OEDEMA MEASUREMENTS	82
2.5.1 Brain Water Content.....	82
2.5.2 Nuclear magnetic resonance studies	82
2.6 BLOOD-BRAIN BARRIER PERMEABILITY	85
2.6.1 Quantitative Evaluation.....	85
2.7 MEASUREMENT OF SP BY ELISA ASSAY	85
2.8 TISSUE PROCESSING	86
2.8.1 Paraffin embedding and sectioning	86
2.8.2 Vibratome sectioning	87
2.9 HISTOLOGY AND IMMUNOHISTOCHEMISTRY	87
2.9.1 Haemotoxylin and Eosin staining	87
2.9.2 Amyloid precursor protein immunohistochemistry.....	88
2.9.3 Substance P Immunohistochemistry	88
2.9.4 Neurokinin-1 receptor Immunohistochemistry	89
2.9.5 Qualitative evaluation of blood brain barrier permeability	89
2.9.6 Confocal Immunohistochemistry.....	90
2.9.7 Electron microscopy	90
2.10 STATISTICAL ANALYSIS	91

CHAPTER 3 CHARACTERISATION OF SUBSTANCE P RELEASE FOLLOWING

TRAUMATIC BRAIN INJURY	92
3.1 INTRODUCTION	93
3.2 METHODS	96
3.2.1 Induction of traumatic brain injury	96
3.2.2 Determination of blood brain barrier permeability	97
3.2.4 ELISA assay.....	98
3.2.4 Statistical Analysis	98
3.3 RESULTS	99
3.3.1 Impact-Acceleration Injury (Weight-drop)	99
3.3.2 Lateral Fluid percussion injury	106
3.3.3 Impact-acceleration Injury (Hydraulic Piston)	106
3.4 DISCUSSION	110

CHAPTER 4 CHARACTERISATION OF N-ACETYL L-TRYPTOPHAN IN TRAUMATIC

BRAIN INJURY112

4.1 INTRODUCTION	113
4.2 METHODS	114
4.2.1 <i>Induction of traumatic brain injury</i>	114
4.2.3 <i>Oedema</i>	116
4.2.4 <i>Nuclear magnetic resonance studies</i>	117
4.2.4 <i>Histology and Immunohistochemistry</i>	119
4.2.5 <i>Statistical analysis</i>	121
4.3 RESULTS	121
4.3.1 <i>confocal microscopy</i>	121
4.3.2 <i>n-acetyl L-tryptophan optimal dosage</i>	121
4.3.3 <i>Nuclear magnetic resonance studies</i>	124
4.3.4 <i>Effects of NAT on Brain water content</i>	126
4.3.5 <i>Effects of NAT on blood brain barrier permeability</i>	126
4.3.6 <i>Effects of NAT on Brain Free Mg²⁺</i>	129
4.3.7 <i>Immunohistochemistry</i>	129
4.4 DISCUSSION	137

CHAPTER 5 EFFECTS OF N-ACETYL L-TRYPTOPHAN ON FUNCTIONAL AND

HISTOLOGICAL OUTCOME FOLLOWING DIFFUSE TRAUMATIC BRAIN INJURY142

5.1 INTRODUCTION	143
5.2 MATERIALS AND METHODS	146
5.2.1 <i>Induction of diffuse impact-acceleration Injury</i>	146
5.2.2 <i>Induction of the lateral fluid percussion Injury</i>	147
5.2.3 <i>Groups</i>	148
5.2.4 <i>Treatment</i>	148
5.2.5 <i>Assessment of motor outcome</i>	149
5.2.6 <i>Assessment of cognitive score</i>	149
5.2.7 <i>Immunohistochemistry</i>	151
5.2.8 <i>Statistical analysis</i>	151
5.3 RESULTS	152
5.3.1 <i>Motor outcome following diffuse impact-acceleration Injury</i>	152
5.3.2 <i>Motor outcome in lateral fluid percussion Injury</i>	152
5.3.3 <i>Cognitive outcome following diffuse impact-acceleration Injury</i>	155
5.3.7 <i>Histology and immunocytochemistry</i>	159
5.4 DISCUSSION	165

**CHAPTER 6 EFFECTS OF ALTERNATIVE NK₁ RECEPTOR ANTAGONISTS ON
FUNCTIONAL OUTCOME FOLLOWING DIFFUSE TRAUMATIC BRAIN INJURY170**

6.1 INTRODUCTION171

6.2 METHODS171

 6.2.1 *Induction of diffuse impact-acceleration Injury*.....171

 6.2.2 *Treatment*.....172

 6.2.3 *Roche NK₁ receptor antagonist dose – response*.....172

 6.2.4 *Assessment of motor outcome*173

 6.2.5 *Statistical analysis*173

6.3 RESULTS174

 6.3.1 *Roche drug optimal dosage*.....174

 6.3.2 *Motor outcome following diffuse impact-acceleration Injury*174

6.4 DISCUSSION.....177

**CHAPTER 7 INHIBITING SUBSTANCE P RELEASE AS A NEUROPROTECTIVE
STRATEGY FOLLOWING DIFFUSE TRAUMATIC BRAIN INJURY178**

7.1 INTRODUCTION179

7.2 METHODS181

 7.2.1 *Induction of diffuse impact-acceleration Injury*.....181

 7.2.2 *1-(2-trifluoromethylphenyl) imidazole dose – response*.....182

 7.2.3 *Groups*183

 7.2.4 *Treatment*.....183

 7.2.5 *Assessment of motor outcome*183

 7.2.5 *Immunohistochemistry*.....184

 7.2.6 *Statistical analysis*184

7.3 RESULTS184

 7.3.1 *1-(2-trifluoromethylphenyl) imidazole dose – response*.....184

 7.3.2 *Motor outcome following diffuse impact-acceleration injury*.....185

 7.3.3 *Histology and immunocytochemistry*.....188

7.4 DISCUSSION.....193

**CHAPTER 8 ESTABLISHING THE THERAPEUTIC WINDOW FOR THE NK₁ ANTAGONIST,
L-732,138, FOLLOWING DIFFUSE TRAUMATIC BRAIN INJURY198**

8.1 INTRODUCTION199

8.2 METHODS201

 8.2.1 *Induction of diffuse impact-acceleration Injury*.....201

 8.2.2 *Treatment*.....202

 8.2.3 *Assessment of motor outcome*202

 8.2.4 *Statistical analysis*203

8.3 RESULTS203

 8.3.1 *Motor outcome following 12 h treatment*203

 8.3.2 *Motor outcome following 24 h treatment*204

8.4 DISCUSSION207

CHAPTER 9 GENERAL DISCUSSION.....210

9.1 CONCLUSION224

BIBLIOGRAPHY198

TABLE OF TABLES

Table 2.1 Relationship between rotational speed and seconds on the rotarod
device.....75

Table of Figures

Figure 1.1 Schematic representation of the biosynthesis of SP and related peptides. (Harrison and Geppetti, 2001).....	34
Figure 1.2 Schematic diagram of human NK ₁ receptor (Regoli et al., 1994)	41
Figure 1.3 Diagrammatic representation of the contribution of SP within the peripheral nervous system (Harrison and Geppetti, 2001).....	55
Figure 2.1 Schematic representation of the impact-acceleration device used to induce diffuse TBI.....	68
Figure 2.2 Schematic representation of the location of the 10 mm diameter stainless steel disc.....	69
Figure 2.3 Impact-acceleration injury model (closed skull-air piston).....	71
Figure 2.4 The rotarod device consisted of a motorised rotating assembly of 18 rods (1 mm in diameter) upon which the animals are placed.....	76
Figure 2.5 Barnes Maze photo	78
Figure 2.6 Object Recognition task.....	81
Figure 3.1 SP stained section from male Sprague-Dawley rats after sham surgery.....	100

Figure 3.2 SP stained section from male Sprague-Dawley rats following the weight-drop model of diffuse TBI.....	101
Figure 3.3 Confocal imaging from the rat cortex (A) SP staining and (B) EB staining from male, sham treated Sprague-Dawley rats. (C) SP staining 5h after moderate/severe TBI and (D) EB staining from male Sprague-Dawley rats 5h after moderate/severe diffuse TBI.	103
Figure 3.4 Confocal imaging from a male Sprague-Dawley rat 5h after injury. Injury results in co-localisation of both SP and EB at a cortical vessel.....	104
Figure 3.5 Plasma concentration levels of SP in male Sprague-Dawley rats following diffuse TBI.	105
Figure 3.6 SP stained section from male Sprague-Dawley rats after sham surgery.....	107
Figure 3.7 SP stained section from male Sprague-Dawley rats after moderate/severe lateral fluid percussion TBI.	108
Figure 3.8 SP stained section from male Sprague-Dawley rats after mild diffuse TBI.	109
Figure 4.1 Confocal imaging of cortex from male, Sprague-Dawley rats after diffuse TBI	122

Figure 4.2 EB brain tissue concentration in male Sprague-Dawley rats following diffuse TBI. A concentration of 2.5mg/kg was determined to be the optimum dosage for n-acetyl L-tryptophan. 123

Figure 4.3 (A) Apparent diffusion coefficients (ADC) maps derived from the diffusion weighted magnetic resonance images obtained from naïve male Sprague-Dawley rats. Naïve treatment resulted in negative water movement while **(B)** following diffuse TBI areas of subcortical hyperintensity indicates the presence of vasogenic oedema. **(C)** When treated with NAT this hyperintensity is decreased and oedema is resolved. **(D)** ADC obtained from the brain following naïve, sham, moderate TBI and moderate TBI + treatment in rats. 125

Figure 4.4 Percentage cortical water content in male rats 5h following moderate/severe TBI and treated with NAT..... 127

Figure 4.5 The level of BBB permeability in male Sprague-Dawley rats as determined via EB penetration into the brain tissue.. 128

Figure 4.6A Phosphorus MR spectrum displaying the effects of NAT on brain free magnesium concentration.. 130

Figure 4.6B Brain intracellular free magnesium concentration following diffuse TBI in male Sprague-Dawley rats following treatment with NAT 131

Figure 4.7 SP stained section from male Sprague-Dawley rats 5hr after moderate/severe diffuse TBI and treated with NAT..... 132

Figure 4.8 SP stained sections from male Sprague-Dawley rats 24hr after moderate/severe diffuse TBI and treated.....	134
Figure 4.9 SP stained sections from male Sprague-Dawley rats 3d after moderate/severe diffuse TBI and treated with NAT.....	135
Figure 4.10 AQP-4 staining within the perivascular astrocyte processes at 5hr following diffuse TBI.	136
Figure 5.1 Motor (Rotarod) function in male shams and male animals treated with saline, n-acetyl L-tryptophan (NAT) and n-acetyl D-tryptophan (NAD) following TBI.	153
Figure 5.2 Motor (Rotarod) function in male animals treated with saline and n-acetyl L-tryptophan (NAT) following lateral FP TBI.	154
Figure 5.3 Cognitive (Object Recognition) function in male shams and male animals treated with saline and n-acetyl L-tryptophan (NAT) following TBI.....	156
Figure 5.4 Cognitive (Barnes Maze) function in male shams and male animals treated with saline and n-acetyl L-tryptophan (NAT) following the weight-drop TBI. (A) Acutely assessed up to 7days after injury (B) Delayed assessment out to 3 weeks after injury..	158
Figure 5.5 Cognitive (Water Maze) function in male shams and male animals treated with saline and n-acetyl L-tryptophan (NAT) following TBI.....	160

Figure 5.6 H&E stained sections from male Sprague-Dawley rats following injury and treatment with NAT.....	161
Figure 5.7 H&E stained hippocampal sections from male Sprague-Dawley rats following injury and treatment with NAT.	163
Figure 5.8 APP stained sections from male Sprague-Dawley rats following injury and treatment with NAT.....	164
Figure 6.1 EB brain tissue concentration in male Sprague-Dawley rats following diffuse TBI. Optimal dosage of AU001 and AU002 was determined to be 3mg/kg and 1mg/kg respectively.	175
Figure 6.2 Motor (Rotarod) function in male animals treated with saline, AU001 and AU002 following TBI.....	176
Figure 7.1 EB brain tissue concentration in male Sprague-Dawley rats following diffuse TBI. A concentration of 21 mg/kg was determined to be the optimum dosage for 1-(2-trifluoromethylphenyl) imidazole.....	186
Figure 7.2 Motor (Rotarod) function in male shams and male animals treated with saline, 1-(2-trifluoromethylphenyl) imidazole (TRIM) and 2-trifluoromethylphenol (TRIMPOH) following TBI.....	187
Figure 7.3 H&E stained sections from male Sprague-Dawley rats following injury and treatment with TRIM and TRIMPOH.	189
Figure 7.4 APP stained sections from male Sprague-Dawley rats following injury and treatment with TRIM and TRIMPOH.	191

Figure 7.5 SP stained sections from male Sprague-Dawley rats following injury and treatment with TRIM and TRIMPOH.	192
Figure 8.1 Motor (Rotarod) function in male animals treated with saline, low dose L-732,138 (NAT-P), high dose of NAT-P and n-acetyl L-tryptophan (NAT) 12 hr following TBI.	205
Figure 8.2 Motor (Rotarod) function in male animals treated with low dose L-732,138 (NAT-P), high dose of NAT-P and n-acetyl L-tryptophan (NAT) 24hr following TBI.	206
Figure 9.1 Schematic illustrating the interrelationships between SP release and inflammation.....	223

ABSTRACT

Traumatic brain injury (TBI) today remains a major health and social problem for both developed and developing countries. It is the leading cause of death and disability under the age of 40, and despite the significance of this public health problem, no effective therapy exists. While a number of factors have been shown to be associated with the development of irreversible tissue injury after TBI, the formation of oedema and opening of the blood brain barrier (BBB) have been shown to be of major significance to outcome. Oedema formation in the brain, when left uncontrolled, results in increased intracranial pressure that may lead to a decrease in brain tissue perfusion, localised hypoxia and ischemia, and ultimately tissue herniation and death. The mechanisms associated with the development of oedema are largely unclear, and accordingly, current therapies are generally ineffective, often resulting in dehydration, hypotension and renal problems.

This thesis describes the characterisation of neurogenic inflammation in the development of post-traumatic brain oedema and functional deficits, and particularly the role of substance P (SP) in mediating their development, using rodent models of both focal and diffuse TBI. Results from this thesis demonstrate that increased SP immunoreactivity, particularly at the level of the vasculature, is a ubiquitous feature of TBI implying a potential role in the breakdown of the blood brain barrier (BBB) following TBI. This was confirmed through the use of the NK₁ receptor antagonists, which attenuated BBB and oedema formation as well as deleterious morphological events such as dark cell change and axonal injury. The NK₁ receptor antagonists also

resulted in an associated improvement in both motor and cognitive deficits, as assessed using a battery of functional outcome tests. Possible mechanisms of action of the NK₁ receptor antagonist included effects on the BBB, SP release, intracellular free magnesium concentration and aquaporin-4 channels. Neuroprotection could be facilitated with administration of a non-lipid permeable NK₁ receptor antagonist in the immediate postinjury period, or up to 12 h after TBI with a lipid permeable NK₁ receptor antagonist, suggesting that this class of drugs have a clinically viable therapeutic window. We conclude that SP has a significant role in the secondary injury process following TBI and may offer a novel target for the development of interventional pharmacological strategies.